KR100953150B1 - 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도 - Google Patents

아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도 Download PDF

Info

Publication number
KR100953150B1
KR100953150B1 KR1020097002099A KR20097002099A KR100953150B1 KR 100953150 B1 KR100953150 B1 KR 100953150B1 KR 1020097002099 A KR1020097002099 A KR 1020097002099A KR 20097002099 A KR20097002099 A KR 20097002099A KR 100953150 B1 KR100953150 B1 KR 100953150B1
Authority
KR
South Korea
Prior art keywords
disease
dementia
compounds
cognitive impairment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097002099A
Other languages
English (en)
Korean (ko)
Other versions
KR20090021228A (ko
Inventor
크레이그 해리슨 밀러
아리엘르 쥬느브아-보렐리아
Original Assignee
타가셉트 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타가셉트 인코포레이티드 filed Critical 타가셉트 인코포레이티드
Publication of KR20090021228A publication Critical patent/KR20090021228A/ko
Application granted granted Critical
Publication of KR100953150B1 publication Critical patent/KR100953150B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097002099A 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도 Expired - Fee Related KR100953150B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US10/379,868 2003-03-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057016343A Division KR101185541B1 (ko) 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도

Publications (2)

Publication Number Publication Date
KR20090021228A KR20090021228A (ko) 2009-02-27
KR100953150B1 true KR100953150B1 (ko) 2010-04-19

Family

ID=32926772

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020097002099A Expired - Fee Related KR100953150B1 (ko) 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도
KR1020057016343A Expired - Fee Related KR101185541B1 (ko) 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도
KR1020127001576A Ceased KR20120014236A (ko) 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도
KR1020097002098A Expired - Fee Related KR101018083B1 (ko) 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020057016343A Expired - Fee Related KR101185541B1 (ko) 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도
KR1020127001576A Ceased KR20120014236A (ko) 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도
KR1020097002098A Expired - Fee Related KR101018083B1 (ko) 2003-03-05 2004-03-04 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도

Country Status (31)

Country Link
US (8) US7098331B2 (https=)
EP (3) EP1947100B1 (https=)
JP (3) JP4663627B2 (https=)
KR (4) KR100953150B1 (https=)
CN (3) CN100526308C (https=)
AR (3) AR043469A1 (https=)
AT (3) ATE394394T1 (https=)
AU (3) AU2004217903B2 (https=)
BR (1) BRPI0409576A (https=)
CA (1) CA2516514C (https=)
CL (1) CL2004000452A1 (https=)
CY (2) CY1110391T1 (https=)
DE (2) DE602004031165D1 (https=)
DK (2) DK1601670T3 (https=)
EA (3) EA019240B1 (https=)
ES (3) ES2389106T3 (https=)
GT (1) GT200400033A (https=)
IL (3) IL170155A (https=)
JO (1) JO2488B1 (https=)
MX (1) MXPA05009386A (https=)
NO (3) NO331920B1 (https=)
NZ (1) NZ541795A (https=)
PA (1) PA8597201A1 (https=)
PE (1) PE20040930A1 (https=)
PL (5) PL215059B1 (https=)
PT (2) PT2085395E (https=)
SI (2) SI1601670T1 (https=)
TW (3) TWI339662B (https=)
UY (1) UY28218A1 (https=)
WO (1) WO2004078752A1 (https=)
ZA (1) ZA200506790B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2010065443A1 (en) * 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
BRPI1014247A2 (pt) * 2009-06-17 2016-04-12 Targacept Inc reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais.
US8802694B2 (en) 2009-12-07 2014-08-12 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands
US20130237550A1 (en) * 2010-03-11 2013-09-12 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
MX385698B (es) * 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
ES3039903T3 (en) 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046554A1 (en) * 1996-06-06 1997-12-11 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
EE04588B1 (et) 1997-10-27 2006-02-15 Neurosearch A/S Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EP1185514A1 (en) 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutical compositions and methods for use
MXPA02002115A (es) 1999-09-14 2002-10-31 Abbott Lab Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. .
EP1225955A1 (en) 1999-11-01 2002-07-31 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2003008559A2 (en) 2001-07-19 2003-01-30 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046554A1 (en) * 1996-06-06 1997-12-11 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission

Also Published As

Publication number Publication date
KR101018083B1 (ko) 2011-03-02
AR043469A1 (es) 2005-07-27
ES2389106T3 (es) 2012-10-23
WO2004078752A1 (en) 2004-09-16
HK1084949A1 (en) 2006-08-11
NO20054120L (no) 2005-10-03
PL394600A1 (pl) 2011-07-18
ATE496046T1 (de) 2011-02-15
EP2085395B1 (en) 2011-01-19
DK1601670T3 (da) 2008-08-25
CN1756754A (zh) 2006-04-05
US20140107164A1 (en) 2014-04-17
IL197890A (en) 2013-11-28
KR20090021228A (ko) 2009-02-27
CN101255155A (zh) 2008-09-03
KR20060006006A (ko) 2006-01-18
UY28218A1 (es) 2005-06-30
US20150164894A1 (en) 2015-06-18
ES2385941T3 (es) 2012-08-03
EA200501425A1 (ru) 2006-02-24
KR20120014236A (ko) 2012-02-16
KR20090021227A (ko) 2009-02-27
NO20092231L (no) 2005-10-03
DE602004013553D1 (de) 2008-06-19
ATE517893T1 (de) 2011-08-15
US20060094732A1 (en) 2006-05-04
IL170155A (en) 2013-08-29
US20110152293A1 (en) 2011-06-23
IL197889A (en) 2013-03-24
ES2309507T3 (es) 2008-12-16
PL378415A1 (pl) 2006-04-03
EP1947100B1 (en) 2011-07-27
CY1110391T1 (el) 2015-04-29
NZ541795A (en) 2008-03-28
EP1947100A1 (en) 2008-07-23
TWI339662B (en) 2011-04-01
EA019240B1 (ru) 2014-02-28
EA200900706A1 (ru) 2009-10-30
CN101550132B (zh) 2012-03-28
HK1116800A1 (en) 2009-01-02
JP2010001296A (ja) 2010-01-07
US8063068B2 (en) 2011-11-22
CA2516514A1 (en) 2004-09-16
TW200927745A (en) 2009-07-01
DK2085395T3 (da) 2011-04-18
DE602004031165D1 (de) 2011-03-03
TW200927746A (en) 2009-07-01
US7098331B2 (en) 2006-08-29
EA014714B1 (ru) 2011-02-28
US20100010042A1 (en) 2010-01-14
US7714001B2 (en) 2010-05-11
AR070570A2 (es) 2010-04-21
PL394604A1 (pl) 2011-07-18
JP2006519868A (ja) 2006-08-31
EP2085395A1 (en) 2009-08-05
NO332293B1 (no) 2012-08-20
JO2488B1 (en) 2009-10-05
SI1601670T1 (sl) 2008-10-31
EP1601670B1 (en) 2008-05-07
PE20040930A1 (es) 2005-02-18
CN100526308C (zh) 2009-08-12
AU2008258188A1 (en) 2009-01-15
HK1130254A1 (en) 2009-12-24
KR101185541B1 (ko) 2012-09-24
PL216979B1 (pl) 2014-06-30
EP1601670A1 (en) 2005-12-07
ATE394394T1 (de) 2008-05-15
ZA200506790B (en) 2006-05-31
US20080293778A1 (en) 2008-11-27
AU2008258187B2 (en) 2010-08-05
AU2004217903A1 (en) 2004-09-16
AU2008258188B2 (en) 2011-02-24
US20040176348A1 (en) 2004-09-09
US8067443B2 (en) 2011-11-29
JP5537084B2 (ja) 2014-07-02
AU2004217903B2 (en) 2010-03-04
NO20091888L (no) 2005-10-03
SI2085395T1 (sl) 2011-05-31
AR070569A2 (es) 2010-04-21
TWI377204B (en) 2012-11-21
TW200505909A (en) 2005-02-16
PT2085395E (pt) 2011-04-20
CL2004000452A1 (es) 2005-05-20
NO20054120D0 (no) 2005-09-05
US20100267776A1 (en) 2010-10-21
AU2008258187A1 (en) 2009-01-15
PL1601670T3 (pl) 2008-10-31
PT1601670E (pt) 2008-07-11
EA200801764A1 (ru) 2008-12-30
MXPA05009386A (es) 2005-11-04
NO331920B1 (no) 2012-04-30
CY1111615T1 (el) 2015-10-07
JP2009292825A (ja) 2009-12-17
PL2085395T3 (pl) 2011-05-31
JP5537085B2 (ja) 2014-07-02
GT200400033A (es) 2005-05-29
JP4663627B2 (ja) 2011-04-06
PL215059B1 (pl) 2013-10-31
PA8597201A1 (es) 2004-09-28
BRPI0409576A (pt) 2006-04-18
US8633222B2 (en) 2014-01-21
CN101550132A (zh) 2009-10-07
EA010870B1 (ru) 2008-12-30
CA2516514C (en) 2012-02-07

Similar Documents

Publication Publication Date Title
AU2008258187B2 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
HK1116800B (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
HK1084949B (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
HK1130254B (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20130325

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20140325

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20150409

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150409

St.27 status event code: N-4-6-H10-H13-oth-PC1903

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301